Physicians. There are three schedules: one for children 0 to 6 years of age, one for those 7 to 18 years of age, and a catch-up immunization schedule for those who start late or fall behind. These schedules reflect current recommendations for use of vaccines licensed by the US Food and Drug Administration and include the following changes from last year:
• The lower age limit for use of live-attenuated influenza vaccine in healthy children has been reduced from 5 years of age to 2 years of age. Live-attenuated influenza vaccine is now available in a liquid formulation that is stable at refrigerator temperatures. The time interval for administration of the second dose of live-attenuated nasal influenza vaccine (when a second dose is indicated) has been reduced from 6 to 4 weeks.
• A single dose of quadrivalent meningococcal conjugate vaccine is now recommended for all adolescents 11 to 18 years of age if not previously administered. For children 2 to 10 years of age at increased risk of meningococcal infection, as defined in the 2006 Red Book, 1 quadrivalent meningococcal conjugate vaccine is recommended and preferred over quadrivalent meningococcal polysaccharide vaccine.
Clinically significant adverse events that follow immunization should be reported to the Vaccine Adverse Event Reporting System (VAERS). Guidance about how to obtain and complete a VAERS form can be obtained on the The online version of this article, along with updated information and services, is 
